Healthcare [ 5/11 ] | Biotechnology [ 54/112 ]
GB | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 10, 23 | -0.44 Increased by +2.22% | -0.40 Decreased by -25.00% |
| Mar 7, 23 | -0.61 Decreased by -35.56% | -0.41 Decreased by -118.98% |
| Nov 8, 22 | -0.32 Increased by +28.89% | -0.55 Increased by +76.03% |
| Aug 9, 22 | -0.44 Decreased by -29.41% | -0.56 Increased by +38.27% |
| May 10, 22 | -0.45 Increased by 0.00% | -0.50 Increased by +20.00% |
| May 9, 22 | -0.45 Increased by +94.63% | -0.50 Increased by +20.00% |
| Mar 1, 22 | -0.45 | -0.41 Decreased by -23.80% |
| Nov 9, 21 | -0.34 | -0.48 Increased by +60.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -17.51 M Decreased by -0.87% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -24.06 M Decreased by -31.96% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -12.48 M Increased by +3.65% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -17.29 M Decreased by -7.01% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -17.36 M Decreased by -26.08% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -18.23 M Decreased by -41.10% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -12.95 M Decreased by -57.70% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -16.16 M Decreased by -135.66% | Decreased by N/A% Decreased by N/A% |
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.